Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer: Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial
Research output: Contribution to journal › Article
Prognostic and Predictive Markers in Primary Breast Cancer - Quality Assurance and Long-term Effects of Adjuvant tamoxifen TreatmentMaria Ekholm, 2018, Lund: Lund University: Faculty of Medicine. 138 p.
Research output: Thesis › Doctoral Thesis (compilation)